Covington Represents Merck on its $1.3B Acquisition of Elanco's Aqua Business

Covington Represents Merck on its $1.3B Acquisition of Elanco's Aqua Business

February 5, 2024

WASHINGTON—Covington advised Merck in its definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile.

The acquisition is expected to be completed by mid-year 2024, subject to approvals from regulatory authorities and other customary closing conditions.

The Covington team included Catherine Dargan, Drew Fischer, and Winsome Cheung.